Mirena® - The levonorgestrel intrauterine system (20 μ/day)

Journal of Drug Evaluation

Volumn 1, Issue 2, 2003, Pages 43-69

  French, Rebecca S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; DIMETICONE; ESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORGESTREL; EVRA PATCH; FLURBIPROFEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; METHYLPREDNISOLONE ACETATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TAMOXIFEN; TRANEXAMIC ACID;

ACNE; AMENORRHEA; BREAST CANCER; BREAST TENDERNESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DEVICE REMOVAL; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DYSMENORRHEA; ENDOCRINE DISEASE; ENDOMETRIUM ABLATION; ENDOMETRIUM TUMOR; EVIDENCE BASED MEDICINE; FEMALE; FEMALE FERTILITY; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; INTRAUTERINE CONTRACEPTIVE DEVICE; IRON DEFICIENCY ANEMIA; MENOPAUSAL SYNDROME; MENORRHAGIA; MOOD DISORDER; NAUSEA; ORAL CONTRACEPTION; OVARY CYST; PELVIC INFLAMMATORY DISEASE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SPOTTING; TERATOGENICITY; UTERUS MYOMA; UTERUS PERFORATION; VOMITING; WEIGHT GAIN;

EID: 1542346964     PISSN: 14791137     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Luukkainen T. Levonorgestrel-releasing intrauterine device. Ann NY Acad Sci 1991;626:43-9
2. Wildemeersch D, Schacht E, Thiery M, Van Kets H. Intrauterine contraception in the year 2001: can intrauterine device be revived with new improved contraceptive technology? Eur J Contracept Reprod Health Care 2000;5:295-304
3. Nilsson CG, Johansson EDB, Luukkainen T. A δ-norgestrel releasing IUD. Contraception 1975;13:503-14
4. Schering Health Care Ltd. Trademarks and countries document. March 1999
5. Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception 1995;52:269-76
6. Sturridge F, Guillebaud J. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Safety 1996;15:430-40
7. Chi IC, Farr G. The non-contraceptive effects of the levonorgestrel-releasing intrauterine device. Adv Contracept 1994;10:271-85
8. Leiras. Investigator's Brochure: Levonorgestrel Intrauterine System. LE 102-97805. Finland: Leiras Oy, 1998
9. Ratsula K. Clinical performance of a levonorgestrel-releasing intracervical device during the first year of use. Contraception 1987;36:659-66
10. Pakarinen P, Luukkainen T, Elomaa K, et al. A 12-month comparative clinical investigation of a levonorgestrel-releasing cervical device situated in the uterine cavity or cervical canal. Contraception 1996;54:187-92
11. Kurunmäki HJ, Toivonen J, Lähteenmäki P, Luukainen T. Intracervical release of levonorgestrel for contraception. Contraception 1981;23:473-85
12. French RS, Cowan FM, Mansour DJA, et al. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health Technol Assess 2000;4:i-vi, 1-107
13. Suvisaari J, Lähteenmäki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception 1996;54:201-8
14. Cox M. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 12-month report. Br J Fam Plann 2000;26:143-7
15. Gupta S, Miller J. A survey of GP views on intrauterine contraception. Br J Fam Plann 2000;26:81-4
16. Bounds W, Robinson G, Kubba A, Guillebaud J. Clinical experience with a levonorgestrel-releasing intrauterine device (LNG-IUD) as a contraceptive and in the treatment of menorrhagia. Br J Fam Plann 1993;19:193-4
17. Sivin I, Mahgoub SE, McCarthy T, et al. Long-term contraception with the levonorgestrel 20 mcg/day (Lng 20) and the copper T 380Ag intrauterine devices: a five-year randomised study. Contraception 1990;42:361-78
18. Andersson K. The levonorgestrel intrauterine system: more than a contraceptive. Eur J Contracept Reprod Health Care 2001;6(Suppl. 1):15-22
19. Rönnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999;78:716-21
20. Faundes A, Alvarez F, Diaz J. A Latin American experience with levonorgestrel IUD. Ann Med 1993;25:149-53
21. Zhu P, Hongzhi L, Ruhua X, et al. The effect of intrauterine devices, the stainless steel ring, the copper T 220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium - a comparative study of three IUDs. Contraception 1989;40:425-38
22. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG. Endometrial morphology during long-term use of levonorgestrel releasing intrauterine devices. Int J Gynecol Pathol 1986;5:235-41
23. Gu Z, Zhu P, Luo H, et al. A morphometric study on the endometrial activity of women before and after one year with LNG IUD in situ. Contraception 1995;52:57-61
24. Critchley HOD, Wang H, Jones RL, et al. Morphological and functional features of the endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum Reprod 1998;13:1218-24
25. Rogers PAW, Au CL, Affandi B. Endometerial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel. Hum Reprod 1993;8:1396-404
26. Hickey M, Dwarte D, Fraser IS. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding. Hum Reprod 2000;15:1509-14
27. McGavigan CJ, Metaxa-Mariatou V, Dockery P, et al. Organon Laboratories prize for the best oral presentation: Large thin walled superficial endometrial vessels, the cause of breakthrough bleeding in women with Mirena. Br J Fam Plann 2000;26:233-6
28. Ludwig H. The morphological response of the human endometrium to long-term treatment with progestational agents. Am J Obstet Gynecol 1982;142:796-808
29. Hourihan HM, Sheppard BL, Bonnar J. The morphological response of blood vessels of the endomterium to low dose oral norethisterone and levonorgestrel. J Obstet Gynaecol 1991;11:47-54
30. Ratsula K, Toivonen J, Allonen H. Patterns of bleeding and body iron stores during the use of a levonorgestrel-releasing intracervical device. Contraception 1988;38:333-40
31. Bobrow C, Cooling H, Bisson D. Amenorrhoea despite displaced levonorgestrel intra-uterine system. Br J Fam Plann 2000;26:105-6
32. Critchley HOD, Wang H, Kelly RW, et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod 1998;13:1210-17
33. Jonsson B, Landgren B, Eneroth P. Effects of various IUDs on the composition of cervical mucus. Contraception 1991;43:447-58
34. Barbosa I, Barkos O, Olsson SE, et al. Ovarian function during use of a levonorgestrel releasing IUD. Contraception 1990;42:51-66
35. Xiao B, Gu S, Wang S, et al. NORPLANT and the levonorgestrel IUD in Chinese family planning programmes. Ann Med 1993;25:161-5
36. Nilsson CG, Lahteenmaki P, Luukanainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel releasing device. Fertil Steril 1984;41:52-5
37. Barbosa I, Olsson SE, Odlind V, et al. Ovarian function after seven years use of a levonorgestrel IUD. Adv Contracept 1995;11:85-95
38. Xiao B, Zhou L, Zhang X, et al. Pharmakinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990;41:353-61
39. Jia M, Zhou L, Ren S, et al. Serum SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD. Adv Contracept 1992;8:33-40
40. Belhadj H, Sivin I, Diaz S, et al. Recovery of fertility after use of the levonorgestrel 20 mcg/d or copper T 380Ag intrauterine device. Contraception 1986;34:261-7
41. Heikkila M, Luukkainen T. Duration of breast feeding and development of children after insertion of a levonorgestrel releasing intrauterine contraceptive device. Contraception 1982;25:279-92
42. Trussell J. Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, et al., eds. Contraceptive Technology, 18th edn. New York: Ardent Media, 2002
43. Backman T, Huhtala S, Blom T, et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. Br J Obstet Gynaecol 2000;107:335-9
44. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/day and the copper T Cu 380Ag intrauterine contraceptive devices: a multicentre study. International Committee for Contraception Research (ICCR). Fertil Steril 1994;61:70-7
45. Masters T, Miskry T, Lowe D, et al. Report of ectopic pregnancies associated with the levonorgestrel system. Br J Fam Plann 1997;23:25-6
46. Ojutiku D, Cutner A, Rymer J. Ectopic pregnancy with levonorgestrel releasing intrauterine system. Br J Fam Plann 1998;24:85-6
47. Guillebaud J. Intrauterine devices. In Contraception: Your Questions Answered. London: Harcourt Publishers Ltd, 1999
48. Sivin I. Hormonal IUD users experience fewer side effects and pregnancy rates as low as copper IUD users. Fam Plann Perspect 1994;26:138-9
49. Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag IUDs. Contraception 1991;44:473-80
50. Sivin I, Alvarez F, Diaz J, et al. Intrauterine contraception with copper and with levonorgestrel: a randomised study of the T Cu 380Ag and levonorgestrel 20 mcg/day devices. Contraception 1984;30:443-56
51. Sivin I, Stern J, Diaz J, et al. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the T Cu 380Ag and levonorgestrel 20 mcg/day devices. Contraception 1987;35:245-55
52. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72
53. Rybo G, Andersson LK, Odlind V. Hormonal intrauterine devices. Ann Med 1993;25:143-7
54. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 1991;77:261-4
55. Lähteenmäki P, Shain RN, Ratsula K, et al. Ensimmaisen vuoden kokemukset levonorgestreeliehkaisimesta [One-year experience of levonorgestrel-releasing intrauterine device]. Duodecim 1991;107:26-31
56. Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of an European multicenter study. Contraception 1987;36:169-79
57. India Council of Medical Research Task Force on IUD. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), Cu T 380Ag, Cu T 220C and Cu T 200B). A 36-month study. Contraception 1989;39:37-52
58. Luukkainen T, Allonen H, Haukkamaa M, et al. Five years' experience with levonorgestrel-releasing IUDs. Contraception 1986;33:139-48
59. Nilsson CG, Allonen H, Diaz J, Luukkainen T. Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study. Fertil Steril 1983;39:187-92
60. Nilsson CG, Luukkainen T, Diaz J, Allonen H. Clinical performance of a new levonorgestrel-releasing intrauterine device. A randomized comparison with a Nova-T copper device. Contraception 1982;25:345-56
61. Nilsson CG, Luukkainen T, Diaz J, Allonen H. Intrauterine contraception with levonorgestrel: a comparative randomised clinical performance study. Lancet 1981;1:577-80
62. World Health Organization. Intrauterine Devices. Annual Technical Report. Geneva: WHO, 1997:79
63. Wang SI., Wu SC, Xin XM, et al. Three years' experience with levonorgestrel-releasing intrauterine device and Norplant-2 implants: a randomized comparative study. Adv Contracept 1992;8:105-14
64. Gao J, Wang SL, Wu SC, et al. Comparison of the clinical performance, contraceptive efficacy and acceptability of levonorgestrel-releasing IUD and Norplant-2 implants in China. Contraception 1990;41:485-94
65. Wang SL [Comparative study of Norplant-2 and levonorgestrel-releasing devices]. Chung Hua Chan Ko Tsa Chih 1990;25:232-4
66. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction: Task Force on Intrauterine Devices for Fertility Regulation. Microdose intrauterine levonorgestrel for contraception. Contraception 1987;35:363-79
67. Heikkilä M, Nylander P, Luukkaninen T. Body iron stores and patterns of bleeding after insertion of a levonorgestrel- or a copper-releasing intrauterine contraceptive device. Contraception 1982;26:465-74
68. Heikkilä M. Puerperal insertion of a copper-releasing and a levonorgestrel-releasing intrauterine contraceptive device. Contraception 1982;25:561-72
69. Heikkilä M, Lähteenmäki P, Luukkainen T. Immediate postabortal insertion of a levonorgestrel-releasing IUD. Contraception 1982;26:245-59
70. El-Mahgoub S. The norgestrel-T IUD. Contraception 1980;22:271-86
71. French R, Cowan F, Mansour D, et al. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. The Cochrane Library. Oxford: Update Software, 2001:1
72. French RS, Cowan FM, Mansour D, et al. Levonorgestrel-releasing (20 μg/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives. Br J Obstet Gynaecol 2000;107:1218-25
73. Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for the treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998;105:592-8
74. Anumba D, Nwabineli JN. Would the levonorgestrel containing intrauterine device (IUD) be a more effective first line treatment for menorrhagia? Br J Obstet Gynaecol 1998;105(Suppl. 17):104 (abstr.321)
75. Lilford RJ. Hysterectomy: will it pay the bills in 2007? Br Med J 1997;314:160
76. Clarke A, Black N, Rowe P, et al. Indications for and outcomes of total abdominal hysterectomy for benign disease: a prospective cohort study. Br J Obstet Gynaecol 1995;102:611-20
77. Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001;357:273-7
78. Andersson K. Intrauterine release of levonorgestrel. A contraceptive and therapeutical system. Acta Obstet Gynecol Scand 1994;74:236-7
79. Barrington JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 1997;104:614-16
80. Fedele L, Bianchi S, Raffaelli R, et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997;68:426-9
81. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990;97:690-4
82. Lähteenmäki P, Haukkamaa M, Puolakka J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. Br Med J 1998;316:1122-6
83. Crosignani PG, Vercellini P, Mosconi P, et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997;90:257-63
84. Kittelsen N, Istre O. A randomised study comparing levonorgestrel intrauterine system (LNG IUS) and trans cervical resection of the endometrium (TCRE) in the treatment of menorrhagia: preliminary results. Gynaecol Endocrinol 1998;7:61-5
85. Milsom I, Anderson ABM, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991;164:879-83
86. Prentice A. Commentary: Promising results but wider recruitment needed. Br Med J 1998;316:1126
87. Paul AC, Choy CC. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1999;106:512
88. Ikomi A, Gupta N. Randomised controlled trial exists of levonorgestrel intrauterine system for menorrhagia. Br Med J 1998;317:1250
89. Lethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus placebo or any other medication for heavy menstrual bleeding. The Cochrane Library. Oxford: Update Software, 2000:4
90. Suhonen S, Holmström T, Lähtenmääki P. Three year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstet Gynecol Scand 1997;76:145-50
91. Andersson K, Stadberg E, Mattson Lå, Rybo G. Intrauterine release of levonorgestrel - a new way of adding progestogen in hormonal replacement therapy. Obstet Gynecol 1992;79:963-7
92. Suvanto-Luukkonen E, Kauppila A. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five year experience. Fertil Steril 1999;72:161-3
93. Raudaskoski T, Lahti E, Kauppila A, et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;172:112-19
94. Gardner FJE, Konje JC, Abrams KR. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000;356:1711-17
95. Neven P. Local levonorgestrel to prevent tamoxifen-related endometrial lesions. Lancet 2000;356:1698-9
96. Tang GWK, Lo SST. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception 1995;51:231-5
97. Belsey EM, Farley TMM. The analysis of menstrual bleeding patterns: a review. Contraception 1988;38:129-56
98. Rodriguez G, Faundes-Latham A, Atkinson LE. An approach to the analysis of menstrual patterns in the critical evaluation of contraceptives. Stud Fam Plann 1976;7:42-51
99. Scholten PC, van Eykeren MA, Christiaens GCML, Haspels AA. Menstrual blood loss with levonorgestrel, Nova-T and Multiload Cu 250 intrauterine devices. In Scholten PC, ed. The Levonorgestrel IUD: Clinical Performance and Impact on Menstruation. Utrecht: University Hospital Utrecht, Thesis, 1989
100. Nilsson CG. Comparative quantitation of menstrual blood loss with a d-norgestrel-releasing IUD and a Nova-T copper device. Contraception 1977;15:379-87
101. Lei ZW, Wu SC, Garceau RJ, et al. Effect of pretreatment counselling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 1996;53:357-61
102. Chi I. An evaluation of the levonorgestrel releasing IUD: its advantages and disadvantages when compared to the copper releasing IUDs. Contraception 1991;44:573-88
103. Mansour MSA, Mansour DJA. The effectiveness of the levonorgestrel intrauterine system (LNG IUS) in the treatment of menorrhagia in a district clinic for abnormal uterine bleeding. Br J Obstet Gynaecol 1998;105(Suppl. 17):323
104. Vercellini P, Aimi G, Panazza S, et al. A levonorgestrel system for the treatment of dysmenorrhoea associated with endometriosis: a pilot study. Fertil Steril 1999;72:505-8
105. Faundes A, Alvarez F, Brache V, Tejada AS. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation. Int J Gynecol Obstet 1988;26:429-33
106. Ulstein M, Steier AJ, Hofstad T, et al. Microflora of cervical and vaginal secretion in women using copper- and norgestrel-releasing IUCDs. Acta Obstet Gynecol Scand 1987;66:321-2
107. Robinson GE, Bounds W, Kubba AA, et al. Functional ovarian cysts associated with levonorgestrel-releasing intrauterine devices. Br J Fam Plann 1989;14:131
108. Sivin I, Stern J, Diaz S, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380 Ag intrauterine contraceptive devices. Am J Obstet Gynecol 1992;166:1208-13
109. Nilsson CG. Fertility after discontinuation of levonorgestrel-releasing intrauterine devices. Contraception 1982;25:273-8
110. Andersson K, Batour I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception 1992;46:575-84
111. British National Formulary, 42nd edn. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, September 2001